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Background: Di-2-ethylhexyl phthalate (DEHP) are added to poly(vinyl chloride)(PVC) infusion tubes as a plasticizer
to ensure tube flexibility. In addition to previously reported disadvantages of DEHP, released DEHP molecules from
PVC tubes can easily interact with surfactants in anticancer drug solutions (i.e., polysorbate 80 for Taxotere®-Inj) and
reduce the solubility of docetaxel in aqueous solution during anticancer drug administration.
Results: In this study, we investigated the in vitro stability of docetaxel in a 0.9% saline solution under an
intravenous administration condition using a PVC tube (high DEHP content) and non-PVC infused tube.
Conclusion: The docetaxel solution circulating through the non-PVC tube had better solution stability than through
the PVC tube(high DEHP content).
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Poly(vinyl chloride) (PVC) is a widely used material for
intravenous infusion tubes for administration of drugs in
clinical practice and blood bags for blood storage after
blood-gathering. Most intravenous infusion PVC tubes
contain di-2-ethylhexyl phthalate (DEHP) as a plasticizer
to provide flexibility of the infusion tube.
Many reports exist regarding DEHP’s toxic effects re-
leased from the PVC tube during intravenous infusion of
aqueous drug solutions [1,2]. Leached DEHP affects hu-
man metabolism [3,4] and can decrease the medicinal
efficacy owing to drug adsorption on the inner surface
of the PVC infusion tube [5]. In addition to the drug ad-
sorption effect due to DEHP release, surfactants(such as
polysorbate 80 [Tween®80] and polyethoxylated castor
oil [Cremophor®EL]) which are meant enhance antican-
cer drug solubility in the solvent, can interact with lea-
ched DEHP from the infusion tube [6]. The plasticizer
can affect the surfactants efficacy and reduce the solubility
of the lyophilic anticancer drug in the aqueous solution,
thus the precipitated anticancer drug (which finally occur* Correspondence: djchung@skku.edu
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unless otherwise stated.concentration difference in anticancer drug solution) may
not retain enough of its original pharmaceutical efficacy.
In this study, to confirm the plasticizer effect in chemo-
therapy using clinical infusion tubes, we investigated the
stability of docetaxel solution (0.9 wt% in saline) circulating
through commercial PVC (high DEHP content), manufac-




The docetaxel solution (anticancer agent, Taxotere®-Inj)
was purchased from Sanofi-Aventis Korea Co. Ltd. (Seoul,
Korea). Commercial PVC infusion tubes (DEHP content:
25 wt%) were purchased from Becton Dickinson Co. Ltd.
(Franklin Lakes, NJ, USA). Another PVC (DEHP content:
10 wt%) tube and non-PVC infusion tubes as control group
were manufactured by Polyscientech Co. Ltd. (Hwaseong,
Korea) using commercial PVC resin (Hanwha Chemical,
Co. Ltd., Seoul, Korea) and polyolefin composite as the
polyethylene (PE) elastomer/polypropylene(PP) elastomer/
polybutadiene(PB) blend(25/50/25 weight ratio), respect-
ively. The PE elastomer (Infuse®, melt index, g/min, 190°C,
2.16 Kg; 5.0) and PP elastomers (Vistamaxx®, melt index,
g/min, 190°C, 2.16 Kg; 3.0) were obtained from Dowtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Composition of the Taxotere®-Inj anticancer drug
Docetaxel (anhydrous) 20 mg
Polysorbate 80 0.54 g
Dehydrated ethyl alcohol 0.395 g (0.5 mL)
Total volume 1 mL
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Chemical Co. Ltd. (Houston, TX, USA), respectively. The
PB elastomer (syndiotactic 1,2- polybutadien, melt index,
g/min, 150°C, 21.2 N; 3.0) was obtained from JSR Corpor-
ation (Japan Synthetic Rubber Corporation, Tokyo, Japan).
The three tubes were adapted for comparison of the
time-dependent solution stability of docetaxel during the
infusion period (approximately 1 hr).
Methods
As shown in Table 1, docetaxel solution for circulation was
prepared as follows: 20 mg of docetaxel (1 mL Taxotere®-
Inj solution containing polysorbate 80) was dissolved in
1 mL of dehydrated ethanol. The solution was dissolved
in 100 mL of 0.9 wt% saline solution as the standard
according to the manufacturer’s instructions (Sanofi-
Aventis Korea).
The infusion tube length (commercial PVC infusion
tube; 85 cm, non-PVC tube and manufactured PVC (low
DEHP content) tube; 100 cm) was determined with the in-
variable inner surface area (75 cm2) based on the tubes
having different inner diameters (commercial PVC tube,
2.8 mm; non-PVC tube and manufactured PVC tube,
2.4 mm). The circulation experiment was conducted using
a micro tubing pump (EYELA MP-3 N, Tokyo Rikakikai
Co. Ltd., Tokyo, Japan) and three types of infusion tubes
were mounted on the tubing pump (Figure 1).
The circulating rate of the drug solution through the
three types of tubes was maintained between 1.2 - 3.0 mL/
min to maintain a constant circulating volume considering
the different inner diameters of the infusion tubes. TheFigure 1 Schematic diagram of the circulation experiment.stability of drug solution was evaluated by measuring the
visible light (600 nm) transmittance changes of the circu-
lating drug solution at predetermined time intervals (every
10 min).
And then concentration differences of docetaxel solution
after circulation was evaluated by measuring the high-
performance liquid chromatography (HPLC). The HPLC
system was equipped with Waters 1525 binary HPLC
pump, Waters 2487 dual λ absorbance detector. HPLC
separation was achieved on a Gemini 5 μ C18 column
(150 × 4.60 mm, 5micron) (Phenomenex®). Column efflu-
ent was monitored at 227 nm. The mobile phase was a
mixture of distilled/deionized water and acetonitrile
(50:50 v/v) with 1 ml/min flow rate [7]. Standard solution
of docetaxel is prepared by dissolving 20 mg of docetaxel
in 100 ml of 0.9 wt% saline solution. And standard solu-
tions were prepared in the range of 40-200 μg/ml. The
retention time of docetaxel was about 8.0 min.
Results and discussion
The visible light transmittance changes at 600 nm of do-
cetaxel solution every 10 min during 1 hr of circulation
is shown in Figure 2.
According to the instructions from the docetaxel solu-
tion manufacturing company, infusion time of docetaxel
solution in the clinical field is within 1 hr, which was
chosen as the entire circulation time for the drug solution.
The docetaxel solution circulating through the commercial
PVC tube showed a significant decrease in transmittance
after 30 min of circulation and the transmittance decreased
to less than 50% of the original value after 50 min. The an-
ticancer drug (docetaxel) precipitated as particles in the
0.9 wt% saline solution after 1 hr circulation. Eventually,
the docetaxel solution passing through the PVC tube be-
came hazy due to the precipitation (Figure 3a).
This phenomenon can be explained by the released
DEPH from the commercial PVC infusion tube during the
circulation process contacting the surfactant molecules
Figure 2 Visible light (600 nm) transmittance change of docetaxel solution during the circulation experiment using commercial PVC
(high DEHP content), manufactured PVC (low DEHP content) and non-PVC infusion tubes.




Figure 3 Stability differences of docetaxel solution after circulation; (a) commercial PVC tube, (b) manufactured PVC tube, (c) non-PVC
tube. Left: before circulation, right: after 1 hr circulation.
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ing complexes through physical interactions [8]. Therefore,
the surfactant content in the Taxotere®-Inj solution was
decreased and the docetaxel solubility in the Taxotere®-Inj
solution was also reduced. The docetaxel molecules were
extracted from the Taxotere®-Inj solution after 1 hr of
circulation, indicating that when a PVC infusion tube is
used for anticancer therapy in the clinical field, antican-
cer drug (i.e., docetaxel) molecules are extracted from
the Taxotere®-Inj solution during intravenous adminis-
tration. Therefore, the effective drug concentration can
be altered during intravenous administration and the ori-
ginal efficacy of the anticancer drug may not be main-
tained during chemotherapy.
But, the change in docetaxel solubility passing through
the non-PVC tube and manufactured PVC tube for the
1 hr circulation was not observed because that the above
mentioned interaction between DEHP and polysorbate
80 was minimized and solution stability was remained
(Figures 3b and 3c).
From our previous report [9], the non-PVC tube showed
almost identical mechanical properties as the commercial
PVC tube in spite of lacking DEHP. And in the case of
manufactured PVC tube, the interaction between small
amount of released DEHP and surfactants was negligible
and docetaxel precipitation was avoided during circula-
tion. In the non-PVC tube and manufactured PVC tube, a
decrease in solubility (as shown by lower transmittance)Figure 4 The concentration differences of docetaxel solution after cir
and non-PVC infusion tubes. Regression equation was calculated Y = 121
concentration in drug (HPLC).was not observed and drug efficacy during clinical drug in-
jection was preserved.
Additionally, the concentration differences of docetaxel
solution before/after circulation were evaluated by the
HPLC. Non-PVC and manufactured PVC tubes as control
group did not show concentration differences. But com-
mercial PVC tube showed noticeable concentration differ-
ence up to 75% decrease after circulation (Figure 4).
From pre-mentioned results, manufactured PVC tube
may be suitable for infusion tube under the only consider-
ation of negligible interaction with surfactants. But, mini-
mum amount of DEHP was adapted for tube processing,
the manufactured PVC tube is not able to recover to ori-
ginal shape after bending (or folding) and is too hard not
to use as infusion tube in clinical field.
Therefore, the non-PVC(Olefin) tube is a good candidate
for the substitution of PVC infusion tube in chemotherapy.
Conclusion
The efficacy of an injected anticancer drug was not pre-
served when commercial PVC infusion tube (containing
DEHP as a plasticizer at high content) was used for clin-
ical drug administration. Conversely, a non-PVC infusion
tube (polyolefin), which did not contain DEHP, main-
tained drug efficacy in chemotherapy. Therefore, alterna-
tive administration using non-PVC tubes and storage bags
should be used widely in medical fields to avoid the risks
of DEHP leaching and reduction of drug efficacy.culation during 60 min using commercial PVC, manufactured PVC
42X + 10750 and correlation was 0.994. Y is the peak area and X is the
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Figure 3: Stability differences of docetaxelsolution after
circulation; (a) commercial PVC tube, (b) manufactured
PVC (less DEHP), (c) non-PVC tube. Left: before circu-
lation, right: after 60 min of circulation.
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